Harvard Bioscience INC 10-Q quarterly reports

Harvard Bioscience, Inc. announced its second quarter 2026 financial results, showing an 11.1% increase in revenue to $22.7 million but a net loss of $2.9 million.

Harvard Bioscience reports significant Q3 2025 losses, faces substantial doubt about its going concern status, and navigates Nasdaq delisting threats amid ongoing debt refinancing efforts.

Harvard Bioscience reported a significant net loss driven by a goodwill impairment and faces substantial doubt about its ability to continue as a going concern due to debt obligations and Nasdaq delisting risk.

Harvard Bioscience's Q1 2025 results reveal a net loss of $50.34 million and highlight substantial doubt about the company's ability to continue as a going concern due to debt refinancing challenges.

Harvard Bioscience experienced a significant revenue decrease in Q3 2024, leading to a net loss and challenges with debt covenants.

Harvard Bioscience's Q2 2024 results show a decrease in revenue compared to the same period last year, impacted by softening global demand and reduced sales to contract research organizations.

Harvard Bioscience reported a decrease in revenue and a net loss for the first quarter of 2024, impacted by softening global demand and other factors.